

HUBR 1186 (10102735)**IN THE CLAIMS**

1-17 (canceled)

18. (previously presented) A method for inducing chondro-/ostrogenic lineage and promoting of cartilage or bone formation in a person comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, and at least one biocompatible or biodegradable matrix selected from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic-coglycolid, polyanhdydrides and collagen to a person in need thereof.
19. (previously presented) A pharmaceutical composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, in combination with an osteoinductive protein, wherein said osteoinductive protein is selected from the group consisting of BMP-2, BMP-7 and a hedgehog protein.
20. (previously presented) A pharmaceutical composition as claimed in claim 19, wherein the ratio of osteoinductive protein : MIA is 1 : 1 to 1 : 20.
21. (canceled)
22. (previously presented) A pharmaceutical composition as claimed in claim 19, wherein the composition comprises a biocompatible matrix.
23. (previously presented) A method for inducing chondro-/ostrogenic lineage and promoting of cartilage or bone formation in a person comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, and at least one biocompatible and/or biodegradable matrix selected

HUBR 1186 (10102735)

from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic-coglycolid, polyanhydrides and collagen, wherein the biocompatible matrix is at least one member selected from the group consisting of hyaluronic acid, alginate, collagen, heparin, polylactic-coglycolid and polyactic-coglycolid derivatives.

24. (previously presented) A method of inducting of the chondro-/osteogenic lineage and promoting cartilage and/or bone formation comprising administering an effective amount of a pharmaceutical composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, at least one biocompatible or biodegradable matrix selected from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic-coglycolid, polyanhydrides and collagen, and an osteoinductive protein selected from the group consisting of BMP-2, BMP-7 and a hedgehog protein to a subject.
25. (canceled)
26. (canceled)
27. (previously presented) The method as claimed in claim 24, wherein the ratio of osteoinductive protein : MIA is 1 : 1 to 1:20.
28. (previously presented) The method as claimed in claim 24 wherein said MIA is combined with said biocompatible matrix.
29. (previously presented) The method as claimed in claim 28, wherein said biocompatible matrix comprises at least one member selected from the group consisting of hyaluronic acid, alginate, collagen, heparin, polylactic-coglycolid and polyactic-coglycolid derivatives.

HUBR 1186 (10102735)

30. (canceled)
31. (canceled)
32. (canceled)
33. (currently amended) A method of treating or repairing at least one of bone or cartilage in a patient comprising administering to a patient in need of bone or cartilage treatment or repair, an effective amount of a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, to the patient to repair the bone or cartilage.
34. (cancelled)
35. (previously presented) A pharmaceutical composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, and a biocompatible matrix, wherein said biocompatible matrix is a three dimensional sponge prepared from collagen, alginate, tricalcium phosphate, and hydroxyapatite.
36. (cancelled)
37. (previously presented) The pharmaceutical composition of claim 35, wherein the biocompatible matrix comprises at least one matrix material selected from the group consisting of alginate, tricalcium phosphate, hyaluronic acid, and calcium sulfate.
38. (new) A method of treating or repairing at least one of bone or cartilage in a patient comprising administering an effective amount of a composition comprising a melanoma inhibiting activity factor, wherein said melanoma inhibiting activity factor is MIA, and an osteoinductive protein to the patient to repair the bone or cartilage.